Financing ·
Q32 Bio Inc. entered into an underwriting agreement on July 14, 2026, to issue and sell 6,027,399 shares of common…
QTTBQ32 Bio Inc.
Q32 Bio Inc. entered into an underwriting agreement on July 14, 2026, to issue and sell 6,027,399 shares of common stock at $18.25 per share and 4,931,506 pre-funded warrants at $18.2499 per warrant. The offering is expected to close on July 16, 2026, with estimated net proceeds of approximately $187.6 million, potentially increasing to $215.8 million if underwriters exercise their option to purchase additional shares. The company intends to use the proceeds for working capital and to support the advancement of bempikibart into future clinical trials. Q32 Bio Inc. is a biotechnology company focused on developing clinical-stage drug candidates.